Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2012 June;58(2) > Minerva Gastroenterologica e Dietologica 2012 June;58(2):101-22

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

  ADVANCES IN INFLAMMATORY BOWEL DISEASES


Minerva Gastroenterologica e Dietologica 2012 June;58(2):101-22

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Maximizing the effect of biologics in inflammatory bowel disease

Souto Rodriguez R. 1, Swoger J. M. 2, Barreiro-De Acosta M. 1, Regueiro M. 2

1 Division of Gastroenterology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; 2 Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center Pittsburgh, PA, USA


PDF  


The chronic course of inflammatory bowel disease (IBD) leads to recurrent episodes of active clinical symptoms, as well as long term complications, including hospitalizations, surgeries, and a decreased quality of life. Biologic agents have been shown to be effective for the induction and maintenance of remission in patients with moderate to severe IBD, and may alter the natural history of disease. Loss of response to biologic therapy is a common problem in clinical practice, the reasons for which are likely multifactorial; antibody development, alterations in drug clearance, and possibly a change to a non-TNF-driven inflammatory mechanism. Several studies have evaluated interventions that may lead to an increased rate of response and an increase in the durability. In this review, we evaluate ways to maximize anti-TNF treatment by administering scheduled therapy, using concomitant immunomodulator therapy, escalating dosage, and switching between biologic agents and classes. Finally, the role of antibody to infliximab (ATI) and infliximab serum trough levels are discussed in the context of optimizing biologic therapy for inflammatory bowel disease.

top of page

Publication History

Cite this article as

Corresponding author e-mail

Mdr7@pitt.edu